Our company works synergistically with the microbiome-targeted pharma and probiotic industries to amplify clinical outcomes of treated patients. We believe the human microbiome is a powerful target for new therapeutic intervention and dietary guidance is a critical factor in modulating the efficacy of these novel interventions. We are dedicated to maximizing the benefit of microbiome-targeted therapeutics by identifying the dietary and lifestyle factors that influence efficacy and safety. We do this by monitoring dietary intake and other relevant factors and correlating this information with clinical outcomes. From this, we are able to provide dietary and lifestyle guidance that maximizes the efficacy of any microbiome-targeted therapeutic, essentially turning non-responders into responders.
The ultimate goal of a clinical trial is to demonstrate safety and efficacy in order to receive approval to commercialize a new drug. Clinical trials often take years and cost millions of dollars to complete. By turning non-responders into responders, we will help tilt the scale towards overall success—for the industry and for the patients.